Analysis of serum epithelium mesenchymal system marker for advanced or metastatic breast cancer treated with Eribulin

Analysis of serum epithelium mesenchymal system marker for advanced or metastatic breast cancer treated with Eribulin - Analysis of serum epithelium mesenchymal system marker for advanced or metastatic breast cancer treated with Eribulin

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000027714

Enrollment

Registered

2017-07-01

Start date

2017-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or metastatic breast cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. histlogically or cytologically confirmed breast cancer 2. advanced or metastatic breast cancer patient treated with Eribulin 3. required baseline laboratory parameters (within 1 weeks before registration) WBC >3,000/mm3 neutrophi > 1,500/mm3 Plt > 100,000/mm3 Hb >9.0g/dL AST <2.0 times ULN and ALT <2.0 times ULN serum creatinine <1.5 time ULN normal cardiac function 4. with life expectancy greater than 3 months 5. written informed consent was obtained

Exclusion criteria

Exclusion criteria: 1. serious complication or past history: with symptomatic heart failure, ischemic heart disease within 6 months, liver cirrhosis, psychological disorder treated by antipsychotic drug, uncontrolable diabetes, etc 2. active infection 3. The anamnesis of the hypersensitivity to Eribulin 4. peripheral neuropathy greater than Grade 3 5. male breast cancer 6. under pregnancy or breast-feeding, and possibility (will) of pregnancy. 7. with doctors decision for exclusion

Design outcomes

Primary

Measure	Time frame
Comparison between change of serum epithelium mesenchymal system marker and clinical response after 3 cycles of Eribulin	—

Secondary

Measure	Time frame
Objective Response Rate, Duration of Response, Progression free survival, Overall survival, Safety	—

Countries

Japan

Contacts

Public ContactKosei Kimura

Osaka medical college Breast Surgery

k.kosei66@gmail.com0726831221

Outcome results